Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab first-line monotherapy in PD-L1 ≥50% advanced NSCLC (single-arm phase II)
ChiCTR2200058403Phase 4Not yet recruiting
- Sponsor
- Cancer Hospirtal Chinese Academy of Medical Sciences
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by Cancer Hospirtal Chinese Academy of Medical Sciences. Primary endpoint: Objective Response Rate. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200058403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058403.